Treatment of Post-Transplant Lymphomas with Anti-B-Cell Monoclonal Antibodies
The treatment of post-transplant lymphomas still needs major improvements in order to put the patient in remission and to retain graft function. Chemotherapy is far too toxic in these patients. A more specific treatment such as anti-B-cell monoclonal antibody is very promising. The cytotoxic effect of antibody relies mainly on complement-induced and antibody-dependent cellular cytotoxicity; apoptosis may also induce tumor cell death. B-ceU antigens expressed on the cell surface are the targets of antibody attack; some specificities may be chosen because of their level of expression or because of signaling induced within the cell. Anti-B-cell antibodies can be produced by genetic engineering in order to be humanized or to carry bispecific Fabs. The efficacy and safety of anti-B-cell monoclonal antibodies (mAbs) in transplant patients have been proven with different antibodies such as anti-CD21/CD24 mAb, anti-CD38 mAb and anti-CD20 mAb. In a retrospective analysis of different centers in France, rituximab (anti-CD20 mAb, Roche Products) achieved an overall 69% remission rate in 34 organ and bone-marrow transplant patients. But the conditions of use of antibody must be better defined, particularly with regard to the immunosuppressive therapy, the type of tumor and the dose of antibody. We must also improve our understanding of the in vivo mechanisms of action of antibody to develop more efficient antibody constructs.
Unable to display preview. Download preview PDF.
- Antoine C, Garnier JL, Duboust A, Bariety J, Stevenson G T, Glotz D (1995) Successful treatment of post-transplant lymphoproMferative disorder with renal graft preservation by monoclonal antibody. Transplant Proc 28:2825Google Scholar
- Benkerrou M, fais JR Leblond V, Durandy A, Sutton L, Bordigoni P, Garnier JL, Le Bidois J, Le Deist F, Blanche S, Fischer A (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 92:3137–3147PubMedGoogle Scholar
- Fisher A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C, Hirn M (1991) Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451–1456CrossRefGoogle Scholar
- Glotz D, Antoine C, Garnier JL, Anderson VA, Leong WS, Worth AT, Stevenson GT (1998) Preliminary observations on the treatment of post-transplant lymphomas by multi-Fc chimeric antibodies. Tumor Targeting 3:46–54Google Scholar
- Link BK, Weiner GJ (1998) Monoclonal antibodies in the treatment of human B-cell malignancies. Leuk Lymph 31:237–249Google Scholar
- Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boué A, Leblond V (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11 [Suppl 1]: S113–S116CrossRefGoogle Scholar
- Starlz TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BR Rosenthal JT, Hakata TR, Shaw BW, Hardesty RL, Atchinson RW, Jaffe R, Bahnson HT (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet I:583–587Google Scholar
- Stevenson GT (1993) Immunotherapy of tumours. In: Lachmann PJ, Peters KD, Rosen FS, Walport MJ (eds) Clinical aspects of immunology, 5th edn. Blackwell Scientific, Oxford, pp 1799–1830Google Scholar
- Swinnen LJ, Costanzo-Nordin MR, Fischer SG, O’Sullivan EL Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fischer RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody 0KT3 in cardiac transplant recipients. N Engl J Med 323:1723–1728PubMedCrossRefGoogle Scholar
- Touraine JL, Bosi E, El Yafi S, et al (1985) The infectious lymphoproliferative syndrome in transplant patients under immunosuppressive therapy. Transplant Proc 17:96–98Google Scholar
- Tutt AL, French RR, IlEdge TM, Honeychurch J McBride HM, Penfold CA, Fearon DT, Parkhouse RME, Klaus GGB, Glennie MJ (1998) Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol 161:3176–3185PubMedGoogle Scholar